The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vivo Bio Tech Ltd
VIRINCHI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.1 pts more than its Software Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vivo Bio Tech Ltd, a promoter group entity of Virinchi Ltd, has filed a disclosure under SEBI's Takeover Regulations for the conversion of 13,15,715 warrants into equity shares on February 24, 2026, allotted on a preferential basis. After conversion, Vivo Bio Tech's direct shareholding in Virinchi rose from 37,84,285 shares (3.48%) to 51,00,000 shares (4.69%), while unconverted warrants reduced from 1,22,15,715 to 1,09,00,000. The promoter group's total economic interest in Virinchi remains unchanged at 14.71% of the share capital (12.69% on a diluted basis), as this is simply a shift from warrants to equity. The total share capital of Virinchi stood at 10,87,96,896 shares of Rs. 10 each.
This is a routine warrant-to-equity conversion by a promoter group entity, so there's no change in overall promoter control or voting power. The shift from warrants to shares marginally strengthens the direct equity stake but does not alter the consolidated promoter holding of 14.71%, meaning no meaningful impact on stock price is expected.